These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 7334388)

  • 1. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.
    Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):1020-3. PubMed ID: 7334388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine in parkinsonism. A long-term study.
    Lees AJ; Haddad S; Shaw KM; Kohout LJ; Stern GM
    Arch Neurol; 1978 Aug; 35(8):503-5. PubMed ID: 666607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should dopamine agonists be given early or late in the treatment of Parkinson's disease?
    Rascol A; Montastruc JL; Rascol O
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):229-32. PubMed ID: 6713321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bromocriptine in the treatment of parkinsonism.
    Fahn S; Cote LJ; Snider SR; Barrett RE; Isgreen WP
    Neurology; 1979 Aug; 29(8):1077-83. PubMed ID: 572493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
    Bouchard S
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):460-5. PubMed ID: 3676921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine in Parkinson disease: further studies.
    Lieberman AN; Kupersmith M; Gopinathan G; Estey E; Goodgold A; Goldstein M
    Neurology; 1979 Mar; 29(3):363-9. PubMed ID: 571981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
    Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
    J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
    Hely MA; Morris JG; Reid WG; O'Sullivan DJ; Williamson PM; Rail D; Broe GA; Margrie S
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):903-10. PubMed ID: 8057111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
    Rinne UK
    Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine in lieu of levodopa for Parkinson's disease.
    Wodak J; Stark R; Gilligan B
    Med J Aust; 1978 Nov; 2(3 Suppl):28-31. PubMed ID: 745578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.